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Background: Spinocerebellar ataxia type 1 (SCA1) is a genetic disorder characterized by severe ataxia associated
with progressive loss of cerebellar Purkinje cells. The mGlu1 metabotropic glutamate receptor plays a key role in
mechanisms of activity-dependent synaptic plasticity in the cerebellum, and its dysfunction is linked to the pathophysiology
of motor symptoms associated with SCA1. We used SCA1 heterozygous transgenic mice (Q154/Q2) as a model for testing
the hypothesis that drugs that enhance mGlu1 receptor function may be good candidates for the medical treatment of
SCA1.
Results: Symptomatic 30-week old SCA1 mice showed reduced mGlu1 receptor mRNA and protein levels in the
cerebellum. Interestingly, these mice also showed an intense expression of mGlu5 receptors in cerebellar Purkinje
cells, which normally lack these receptors. Systemic treatment of SCA1 mice with the mGlu1 receptor positive allosteric
modulator (PAM), Ro0711401 (10 mg/kg, s.c.), caused a prolonged improvement of motor performance on the rotarod
and the paw-print tests. A single injection of Ro0711401 improved motor symptoms for several days, and no tolerance
developed to the drug. In contrast, the mGlu5 receptor PAM, VU0360172 (10 mg/kg, s.c.), caused only a short-lasting
improvement of motor symptoms, whereas the mGlu1 receptor antagonist, JNJ16259685 (2.5 mg/kg, i.p.), further
impaired motor performance in SCA1 mice. The prolonged symptomatic benefit caused by Ro0711401 outlasted
the time of drug clearance from the cerebellum, and was associated with neuroadaptive changes in the cerebellum,
such as a striking reduction of the ectopically expressed mGlu5 receptors in Purkinje cells, increases in levels of total
and Ser880-phosphorylated GluA2 subunit of AMPA receptors, and changes in the length of spines in the distal
dendrites of Purkinje cells.
Conclusions: These data demonstrate that pharmacological enhancement of mGlu1 receptors causes a robust
and sustained motor improvement in SCA1 mice, and lay the groundwork for the development of mGlu1
receptor PAMs as novel “cerebellum-specific”, effective, and safe symptomatic drugs for the treatment of SCA1
in humans.
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Spinocerebellar ataxia type-1 (SCA1) is an inherited
neurological disease caused by expansion of an unstable
CAG repeat in the ataxin-1 (ATXN1) gene, which leads
to progressive degeneration of Purkinje cells in the cere-
bellar cortex. SCA1 patients show loss of coordination
of the limbs and trunk, unstable gait, dysarthric speech,
and nystagmus, as well as extrapyramidal and dysauto-
nomic symptoms and cognitive dysfunction [1,2]. Several
mouse models have been generated over the years in an
attempt to shed light on ATXN1 function and its role in
the pathogenesis of SCA1. These mouse models recap-
itulate the histopathological and behavioral hallmarks of
SCA1 patients. For example, SCA1154Q/2Q mice show
progressive degeneration of Purkinje cells, ataxia, muscle
wasting, severe kyphosis, and premature death between
35 and 45 weeks of age [3]. A current theory on the
pathogenesis of SCA1 is that polyglutamine expansion
disrupts the physiological interaction between ATXN1
and nuclear proteins regulating gene transcription and
RNA processing, such as Capicua, retinoic acid or-
phan receptor-α (RORα), and RBM17 [4]. None of
these mechanisms can be easily targeted by pharmaco-
logical interventions, and there is currently no treat-
ment for SCA1 and other types of spinocerebellar
ataxia.
Although nuclear mechanisms lie at the core of the
disorder, type-1 metabotropic glutamate receptors (mGlu1
receptors) are tightly linked to the pathophysiology of
SCA1. mGlu1 receptors are coupled to Gq/11 and their
activation stimulates the hydrolysis of phosphatidyinositol-
4,5-bisphosphate with ensuing formation of inositol-1,4,5-
trisphosphate (InsP3) and diacylglycerol (DAG). InsP3
stimulates Ca2+ release from intracellular stores, whereas
DAG activates protein kinase C (PKC) [5]. The cognate
mGlu5 receptor is also coupled to inositol phospholipid
hydrolysis but with diversity of Ca2+ signaling. In recom-
binant cells, activation of mGlu1α receptors induces an in-
crease in intracellular free Ca2+ consisting of an initial
transient peak followed by a steady plateau phase, whereas
activation of mGlu5a receptors induces intracellular Ca2+
oscillations [6]. Another difference between mGlu1 and
mGlu5 receptors is the developmental pattern of expres-
sion. mGlu1 receptors predominate in cerebellar Purkinje
cells [7], where their expression levels increase with age
[8]. In contrast, expression and function of mGlu5 recep-
tors is high in the first 2 weeks of postnatal life and de-
clines afterwards [9].
mGlu1 receptors are essential for the induction of
long-term depression (LTD) at both parallel fiber and
climbing fiber-Purkinje cell synapses, a form of activity-
dependent synaptic plasticity underlying cerebellar motor
learning and vestibule-ocular reflex adaptation [10-14].
Mice with genetic deletion of mGlu1 receptors show aprofound defect of cerebellar LTD, motor coordination
and conditioned eyeblink reflex [14-17], and all these de-
fects are corrected by selective re-introduction of mGlu1
receptors in Purkinje cells [18].
Interestingly, a defective expression/activity of mGlu1
receptors or downstream signaling molecules is found in
genetic mouse models of ataxia [19-21], and autoanti-
body directed against mGlu1 receptors are occasionally
present in patients with paraneoplastic ataxia associated
with Hodgkin’s lymphoma [22].
The link between SCA1 and mGlu1 receptors is sup-
ported by the following observations: (i) one of the earli-
est pathological events in SCA1 B05/+ mice is the
presence of cytoplasmic vacuoles containing mGlu1 re-
ceptors in cerebellar Purkinje cells [23]; (ii) in condi-
tional SCA1[82Q] mice, motor recover after interruption
of transgene expression is associated with reappearance
of mGlu1 receptors at parallel fiber-Purkinje cell synap-
ses [24]; (iii) homozygous staggerer mutant mice, which
are considered as an “extreme” mouse model of SCA1,
lack mGlu1 receptor-mediated slow synaptic transmis-
sion at parallel fiber-Purkinje cell synapses and show low
expression levels of mGlu1 receptors in the cerebellum
[21]; and (iv) expression of genes encoding for mGlu1
receptor signaling proteins, such as Homer-3 and type-1
InsP3 receptors, is altered in cerebellar Purkinje cells of
SCA1 B05 mice [25,26]. These studies laid the ground-
work for targeting mGlu1 receptors in the treatment of
SCA1. New subtype-selective drugs that amplify mGlu1
receptor function by interacting with a site different
from the glutamate recognition site are available [27-29].
These positive allosteric modulators (PAMs) or “en-
hancers” are highly promising from a therapeutical
standpoint because they exclusively recruit mGlu recep-
tors that are activated by endogenous glutamate, thus
acting in an “activity-dependent” manner. We now re-
port that, systemic administration of a selective mGlu1
receptor PAM to SCA1 mutant mice, causes long-lasting
improvements in motor symptoms associated with adap-
tive changes in cerebellar neuroplasticity.
Results
Changes in the expression of mGlu1α and mGlu5
receptors in Purkinje cells of symptomatic SCA1 mice
We measured mGlu1 receptor mRNA and mGlu1α re-
ceptor protein levels by real-time PCR and immunoblot-
ting, respectively. The mGlu1α antibody detected a major
band at 140 kDa corresponding to the deduced molecular
size of receptor monomers. Labeling was highly specific
because the band disappeared in the cerebellum of
mGlu1-deficient crv4 mice [17] (not shown). mGlu1α
mRNA and protein levels in the cerebellum did not
differ between 4-week old presymptomatic SCA1 mice
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Figure 1 Reduced mGlu1 receptor mRNA and protein levels in the cerebellum of symptomatic SCA1 mice. mGlu1 receptor mRNA and
mGlu1α receptor protein levels in the cerebellum of presymptomatic and symptomatic SCA1 mice (and their age-matched wild-type littermates)
are shown in (A) and (B), respectively. Values are means ± S.E.M. of 3–4 mice per group. *p < 0.05 (Student’s t test) vs. the corresponding
wild-type mice; t values = 5.3 (mRNA values normalized to GAPDH); 6.5 (mRNA values normalized to calbindin); and 7.075 (densitometric
analysis of immunoblots). Immunohistochemical analysis of mGlu1α receptors and calbindin in the cerebellum of SCA1 mice and wild-type
littermates are shown in (C) and (D).
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large reductions in mGlu1 receptor mRNA levels, which
were equally seen when data were normalized to bothGAPDH and calbindin mRNA levels (Figure 1B). mGlu1α
receptor protein levels were also reduced by about 50% in
the cerebellum of symptomatic SCA1 mice, at least
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(Figure 1B). Immunohistochemical analysis showed a
reduced intensity of mGlu1α receptor staining in symp-
tomatic SCA1 mice, which was particularly evident in the
dendritic arborization of Purkinje cells (Figure 1C). High
magnification analysis showed that mGlu1α receptor pro-
tein expression was also reduced at least in some Purkinje
cells that appeared morphologically intact and were regu-
larly stained with anti-calbindin antibody (Figure 1D).
Taken together, these data indicated that a loss of mGlu1α
receptors in Purkinje cells was associated with the patho-
logical phenotype of SCA1 mice.
We extended the analysis to mGlu5 receptors, which
are normally expressed at low levels in the adult cere-
bellum and are nearly absent in Purkinje cells (see Figure 2C).
The band at 140 kDa corresponding to mGlu5 receptor
monomers was absent in the cerebral cortex of mGlu5
receptor knockout mice (not shown) confirming the
specificity of the antibody. Expression of mGlu5 recep-
tors was unaffected in the cerebellum of presymptom-
atic SCA1 mice (Figure 2A). In contrast, we found a
large increase of mGlu5 receptor protein levels and a
trend to an increase in the transcript of mGlu5 recep-
tors in symptomatic SCA1 mice (Figure 2B). The in-
duction of mGlu5 receptor protein was fully confirmed
by immunohistochemical analysis, where Purkinje cells
from only symptomatic SCA1 mice were stained by anti-
mGlu5 receptor antibodies. Both cell bodies and dendrites
of Purkinje cells expressed mGlu5 receptors in symptom-
atic SCA1 mice (Figure 2C-E). Confocal microscopy ana-
lysis showed a perisomatic localization of mGlu5 receptors
in Purkinje cells of SCA1 mice (Figure 2E).
Pharmacological enhancement of mGlu1 receptors caused
a long-lasting improvement of motor coordination in
SCA1 mice
Thirty-week old SCA1 mice showed a reduced motor
performance on the rotarod, and signs of ataxia in the
paw print test. However, the extent of motor impairment
in these mice was variable, with some of them showing a
mild motor impairment and other a severe impairment
at the rotarod. Motor performance in SCA1 mice with
mild impairment was slightly but significantly improved
by a single systemic administration with the mGlu1 re-
ceptor PAM, Ro0711401 (10 mg/kg, s.c.) at all times
from 30 to 90 min post-injection (Figure 3A). Injection
of Ro0711401 had no effect on motor performance in
wild-type littermates (Figure 3B). In contrast, single injection
of the mGlu1 receptor negative allosteric modulator
(NAM), JNJ16259685 (2.5 mg/kg, i.p.), markedly reduced
motor performance both in wild-type and 30-week old
SCA1 with mild motor impairment at 30 and 60 min
post-injection (Figure 3C). In mice with severe impair-
ment of motor performance (latency to fall < 100 sec onthe rotarod), a single injection with Ro0711401 caused a
large improvement of motor coordination, which was vis-
ible at 60 and 90 min post injection (Figure 3D,E). To ex-
clude the possibility that Ro0711401 increased motor
performance by an off-target effect, we tested the com-
pound in mGlu1-deficient crv4 mice, which display severe
ataxia [17]. As opposed to what observed in SCA1 mice, a
single injection of Ro0711401 (10 mg/kg, s.c.) did not im-
prove motor performance on the rotarod in crv4 mice
(Figure 3F).
We next examined the temporal profile of response to a
single injection of Ro0711401 in SCA1 mice by assessing
motor performance on the rotarod every day for 6 days.
Surprisingly, a single administration of Ro0711401 caused
a long-lasting improvement in motor performance, which
was maintained to the same extent at least for 6 days
(Figure 4A). Again, the drug had no effect in wild-type
littermates (Figure 4C). We also tested motor perform-
ance in response to daily administrations of Ro0711401
(10 mg/kg, s.c., for 6 days) showing no development of
tolerance to the motor-improving effect of the drug
(Figure 4B).
We also examined whether pharmacological enhance-
ment of mGlu5 receptors could also be beneficial in
SCA1 mice using the selective mGlu5 receptor PAM,
VU0360172 (10 mg/kg, s.c.). A single administration of
VU0360172 transiently improved motor symptoms in
SCA1 mice at 60 and 90 min post-injection (Figure 5A).
As opposed to Ro0711401, VU0360172 had no enduring
effects on motor behavior, and there was no significant
difference between mice treated with VU0360172 and
those treated with vehicle when motor performance was
assessed at 1 to 6 days post-injection (Figure 5B).
Potential mechanisms underlying the long-lasting
improvement in motor symptoms caused by Ro0711401
in SCA1 mice
a) Measurements of Ro0711401 levels in the cerebellum
We first examined whether the long-lasting effects of
Ro0711401 in symptomatic SCA1 mice were due to a
slow clearance of the drug from the cerebellum. Drug
levels were detected by HPLC/MS-MS at 30–120 min
after a single injection of Ro0711401 (10 mg/kg, s.c.),
confirming that the drug crosses the blood–brain bar-
rier. However, levels became undetectable at 24 hours
post-injection, excluding that the enduring increase in
motor performance was due to the maintenance of
Ro0711401 in cerebellar tissue (Table 1).
b) Changes in mGlu1α and mGlu5 receptor
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Figure 2 Appearance of mGlu5 receptors in Purkinje cells of symptomatic SCA1 mice. mGlu5 receptor mRNA and protein levels in the
cerebellum of presymptomatic and symptomatic SCA1 mice (and their age-matched wild-type littermates) are shown in (A) and (B), respectively.
Values are means ± S.E.M. of 4 mice per group. *p < 0.05 (Student’s t test) vs. the corresponding wild-type mice. t = 10 (densitometric analysis of
immunoblots). Immunohistochemical analysis of mGlu5 receptors in the cerebellum of SCA1 mice and wild-type littermates are shown in (C) and
(D). Confocal microscopy analysis of mGlu5 receptors in Purkinje cells of wild-type and symptomatic SCA1 mice is shown in (E). Note the somatic
and perisomatic immunostaining which excludes the cell nucleus.
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Ro0711401 could induce adaptive changes in the expres-
sion of mGlu1α and mGlu5 receptors in the cerebellum.
Immunohistochemical analysis carried out at 6 days
post-injection confirmed the reduced expression of mGlu1α
receptors in the cerebellum of SCA1 mice, which wasunaltered by drug treatment (Figure 6A). In contrast,
single injection of Ro0711401 abolished the increase in
the expression of mGlu5 receptors seen in the Purkinje
cells of symptomatic SCA1 mice (Figure 6B). These
data raised the interesting possibility that mGlu1 re-
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Figure 3 Acute treatment with the mGlu1 receptor PAM, Ro0711401, improves motor performance in symptomatic SCA1 mice. Effect
of Ro0711401 on the rotarod in symptomatic SCA1 mice with mild motor impairment (A); values are means ± S.E.M. of 4 mice per group.
*p < 0.05 vs. corresponding values at time 0; Two-way ANOVA for repeated measures + Fisher’s LSD: F(3,21) = 7.621 and F(1,21) = 10.176 for
time and treatment, respectively; and in wild-type littermates (B); data are means ± S.E.M. of 7 mice per group. Lack of effect of
JNJ16259685 in SCA1 mice with mild motor impairment and wild-type (C), where data are means ± S.E.M. of 4 mice per group; *p < 0.05 vs.
respective values at time 0. Two-way ANOVA for repeated measures + Fisher’s LSD; F(3,18) = 34.38 and F(1,18) = 7.24 for time and treatment,
respectively. Effect of Ro0711401 in symptomatic SCA1 mice with severe motor impairment (D); values are means ± S.E.M. of 5 mice per
group. *p < 0.05 vs. corresponding values at time 0; Two-way ANOVA for repeated measures + Fisher’s LSD; F(3,12) = 11.177 and F(4,39) = 9.982 for time
and time x treatment, respectively. Paw print test in SCA1 mice with severe motor impairment and wild-type acutely treated with Ro0711401 (E). Data
were quantified by calculating the coefficient of variation of 5 consecutive strides with the left paw of each mouse. Values are means ± S.E.M. of 9
mice. *p < 0.05 (One-Way ANOVA plus Fisher’s PLSD) vs. SCA1 mice before the treatment. Representative traces were carried out 5 min prior and 60
min after drug injection. Motor performance on the rotarod of mGlu1-deficient crv4 mice and wild-type mice 1 hour following s.c. injection of vehicle
or Ro0711401 (F). Values are means + S.E.M. of 4 mice per group.
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ine this possibility, we measured mGlu5 receptors in
wild-type mice treated with the mGlu1 receptor NAM,
JNJ16259685. Mice were killed 6 days following a singleinjection (“acute treatment”) or after 6 daily injections
(“chronic treatment”) with JNJ16259685 (2.5 mg/kg, i.p.).
Under both paradigms of administration, pharmacological
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Figure 4 Pharmacological enhancement of mGlu1 receptors causes a prolonged symptomatic benefit in SCA1 mice. Motor performance
on the rotarod in SCA1 mice with severe motor impairment at different times following a single injection of vehicle or Ro0711401 is shown in
(A), where values are means ± S.E.M. of 6 mice per group. *p < 0.05 vs. the corresponding values at time 0; Two-way ANOVA for repeated
measures + Fisher’s LSD; F(7,35) = 2.48, F(1,10) = 21.003, and F(7,35) = 2.321 for time, treatment, and time x treatment, respectively. Motor performance
in SCA1 mice with mild impairment treated daily with Ro0711401 is shown in (B), where values are means ± S.E.M. of 6 mice per group. *p < 0.05 vs.
the corresponding pre-treatment values; Two-way ANOVA for repeated measures + Fisher’s LSD; F(5,15) = 4.248, F(1,11) = 37.408 and F(5,15) = 6.078 for time,
treatment and time x treatment, respectively. The lack of motor effect of single injection of Ro0711401 in wild-type littermates is shown in (C), where
values are means ± S.E.M. of 4 mice per group.

















































Single injection of vehicle 
or VU0360172 
Figure 5 A Single injection of the mGlu5 receptor PAM, VU0360172, causes a short-lasting improvement of motor performance in
symptomatic SCA1 mice. Motor performance on the rotarod in SCA1 mice with severe motor impairment treated with a single injection of
VU0360172 is shown. In (A), values are means ± S.E.M. of 5 mice per group. *p < 0.05 vs. the corresponding values at time 0; Two-way ANOVA for
repeated measures + Fisher’s LSD; F(3,12) = 5.921, F(3,12) = 5.629 for time and time x treatment, respectively. In (B), values are means ± S.E.M. of 4
mice per group.
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Table 1 Measurements of drug levels by HPLC/MS-MS in
the cerebellum of symptomatic SCA1 mice at 30–120 min
after a single injection of Ro0711401 (10 mg/kg, s.c.)
Time after injection Cerebellar Ro0711401 levels
(pg/mg tissue)
30 min 211 ± 20
60 min 135 ± 10
90 min 100 ± 9
120 min 100 ± 40
240 min 80 ± 30
24 hours N.D.
Values are means ± S.E.M. of 3 animals per time point. N.D. = not detectable.
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type mice (Figure 6C). Immunohistochemical analysis
showed a strong mGlu5 receptor staining in Purkinje
cells of mice treated with JNJ16259685 (Figure 6D).
c) A single injection of Ro0711401 did not change the
distribution profile of vGluT2 immunostaining in
the cerebellar cortex of SCA1 mice
Knowing that deletion of mGlu1 receptors causes an
impairment of developmental elimination of redundant
climbing fibers to Purkinje cell synapses [30], we examined
the distribution pattern of putative vGluT-2-immunoreactive
climbing fibers in the cerebellar cortex of wild-type or SCA1
mice 6 days following an acute injection of vehicle or
Ro0711401. SCA1 mice showed a large increase in vGluT-2
immunoreactivity in the granular layer of the cerebellar cor-
tex (Figure 7), which is suggestive of an increased number of
en passant climbing fibers projecting to Purkinje cells. This
was consistent with the decreased pruning of climbing fiber
terminals found in other mouse models of SCA1 [31]. Treat-
ment with Ro0711401 did not change the distribution profile
of vGluT-2 immunoreactivity in both wild-type and SCA1
mice (Figure 7).
d) A single injection of Ro0711401 caused adaptive
changes typically associated with activity-dependent
synaptic plasticity in the cerebellum
We reasoned that the long-lasting improvement in
motor performance caused by a single injection of
Ro0711401 could reflect the induction of adaptive
mechanisms associated with activity-dependent synap-
tic plasticity and cerebellar motor learning. Changes in
the expression, Ser-880 phosphorylation, and cluster-
ing of the Ca2+-impermeable GluA2 subunit of AMPA
receptors, have been associated with the induction and
expression of cerebellar LTD [32-37]. Levels of both
unphosphorylated and Ser880-phosphorylated GluA2
subunit were found to be significantly elevated in thecerebellum of SCA1 mice 6 days following a single in-
jection of Ro0711401 (Figure 8A). This treatment did
not cause changes in the number of dendritic spines in
Purkinje cells of SCA1 mice (Figure 8B). However, in-
jection of Ro0711401 did cause changes in the morph-
ology of dendritic spines that might be associated with
motor learning. The distribution analysis of a fixed
number of dendritic spines of Purkinje cells in relation
to their length showed a shift to the right in symptomatic
SCA1 mice as compared to age-matched wild-type mice.
A single injection of Ro0711401 in SCA1 mice increased
the number of “short” dendritic spines (i.e. spines with
length between 0.3 and 0.5 μm), changing the pattern of
distribution in a way similar to that found in wild-type
mice (Figure 8C).
Discussion
We confirmed here the reduced expression of mGlu1 re-
ceptors in the cerebellum of SCA1 mice (see Introduc-
tion and references therein). At least the reduction of
the transcript of mGlu1 receptors was confirmed when
values were normalized to calbindin mRNA levels, sug-
gesting that receptor expression was reduced in indi-
vidual Purkinje cells. Interestingly, Purkinje cells of
symptomatic SCA1 mice showed an intense mGlu5 re-
ceptor immunoreactivity, which was nearly absent in
Purkinje cells from control mice. In the cerebellum,
the mGlu5 receptor is highly expressed early after
birth, and then progressively disappears concomitantly
with the appearance of mGlu1 receptors [9,38]. Our
data raise the interesting possibility that in Purkinje
cells mGlu1α and mGlu5 receptors are mutually exclu-
sive and that the highly expressed mGlu1α receptor
maintains the mGlu5 receptor repressed in the adult
life. Accordingly, (i) the mGlu5 receptor reappeared in
Purkinje cells of SCA1 mice, which were characterized
by a reduced expression of mGlu1α receptors; (ii) amp-
lification of the residual mGlu1α receptors (or other
mGlu1 splice variants) with Ro0711401 repressed again
the mGlu5 receptor in SCA1 mice; and (iii) pharmaco-
logical blockade of mGlu1 receptors with JNJ16269685
markedly enhanced the expression of mGlu5 receptors in
Purkinje cells. A similar scenario was seen in mice sub-
jected to experimental autoimmune encephalomyelitis
(EAE) or in autoptic cerebellar samples from patients with
multiple sclerosis, in which a reduced expression of
mGlu1α receptors was associated with the reappearance
of mGlu5 receptors in Purkinje cells [39]. mGlu1 and
mGlu5 receptors are both coupled to phospholipase Cβ,
the enzyme that cleaves PtdIns-4-5-P2 into InsP3 and
DAG. However, the dynamics of InsP3-stimulated intracel-
lular Ca2+ release differs between the two receptors, show-
ing a peak in cytosolic Ca2+ followed by a plateau phase,
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Figure 6 Changes in the expression of mGlu1α or mGlu5 receptors following treatments with Ro0711401 or JNJ16259685.
Immunohistochemical analysis of mGlu1α and mGlu5 receptors in cerebellar serial sections of symptomatic SCA1 mice 6 days following a single
s.c. injection of vehicle or Ro0711401 (10 mg/kg) is shown in (A) and (B), respectively. Note the disappearance of mGlu5 receptors from Purkinje
cells after treatment with Ro0711401. Immunoblot analysis of mGlu5 receptors in wild-type mice treated acutely or repeatedly with JNJ16259685
(2.5 mg/kg) is shown in (C). Control mice were treated daily i.p. with vehicle for 6 days. The group of mice indicated as “single injection of
JNJ16259685” received a 6-day treatment of vehicle followed by a single administration of JNJ16259685. The third group of mice received daily
injections of JNJ16259685 for 6 days. A representative immunoblot of mGlu5 receptor is shown. Densitometric values are means ± S.E.M. of
5 mice per group. *p < 0.05 vs. mice treated with vehicle (One-way ANOVA + Fisher’s LSD). F(2,12) = 13.124. Immunohistochemical analysis of
mGlu5 receptors in the cerebellum of the same mice is shown in (D).
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linked to basic processes of cell biology, such as cell prolif-
eration, differentiation, and survival [41,42], whereas asingle peaked Ca2+ response might be a feature of a ma-
ture excitable cell. Thus, the early expression of mGlu5 re-







































Figure 7 Ro0711401 treatment does not change the distribution profile of vGluT2 immunostaining in the cerebellum of wild-type and
symptomatic SCA1 mice. Wild-type and SCA1 mice (n = 3 per group) received a single s.c. injection of vehicle or Ro0711401 (10 mg/kg), and
were killed after 6 days. Representative sections from 2 individual mice per group are shown. Note the increased vGluT2 immunostaining in the
cerebellar granular layer of SCA1 mice.
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http://www.molecularbrain.com/content/6/1/48maturation, which are override by the “synaptic” mGlu1
receptor when maturation is completed. The reappearance
of mGlu5 receptors associated with the reduced expres-
sion (or function) of mGlu1α receptors might be viewed
as a sterile attempt to compensate for the loss of mGlu1α
receptors, or more simply a restatement of a developmen-
tal pattern of intracellular calcium mobilization associatedwith Purkinje cell pathology. Remarkably, treatment with
the mGlu5 PAM, VU0360172, which was proven to be
centrally active after systemic administration [43,44]
caused only small and transient improvements in motor
performance in SCA1 mice.
In contrast, pharmacological enhancement of the defect-
ive mGlu1 receptor caused a prolonged improvement of
Vehicle
GluA2 subunit > < 106 kDa
< 45 kDa
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Figure 8 Neuroadaptive changes caused by a single injection of Ro0711401 in the cerebellum of SCA1 mice. Levels of total and
Ser880-phosphorylated GluA2 subunit of AMPA receptors in the cerebellum of symptomatic SCA1 mice 6 days following a single injection of vehicle
or Ro0711401 (10 mg/kg, s.c.) is shown in (A). Densitometric values are means ± S.E.M. of 4–5 mice per group. *p < 0.05 vs. mice treated with vehicle
(Student’s t test). t = − 3.192 (total GluA2) and 4.311 (p-GluA2). Spine density in 3–4 dendritic branchlets of Purkinje cells from wild-type or SCA1 mice
6 days after a single injection of vehicle or Ro0711401 is shown in (B), where values are means + S.E.M. of 4 mice per group. The distribution of
dendritic spines in relation to their lengths in distal dendrites of Purkinje cells 6 days after a single injection of vehicle or Ro0711401 in
symptomatic SCA1 mice or after injection of vehicle in wild-type littermates is shown in (C). The length of 200 spines per mouse was measured.
Values are means ± S.E.M. of 5 individual determination for groups. In (C) spines were identified and measured using Image Pro Plus Software.
Representative images and distribution spine analysis are shown. Data are means ± S.E.M. of 4 mice per group. *p < 0.05 (Two-Way ANOVA + Bonferroni’s
t tests) as indicated in individual groups of columns. F(13,84) = 87.47.
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mGlu1 receptor PAM, Ro0711401, which has nanomolar
affinity for mGlu1 receptors, that is systemically active,
and shows an elimination half-life < 2 hours [45]. Systemic
injection of Ro0711401 was shown to reduce the fre-
quency of spike-and-wave discharges in a rat model of ab-
sence epilepsy [46], and to improve motor signs in EAE
mice [39]. Of note, treatment with Ro0711401 had no ef-
fect on motor behavior in control mice or in presymptom-
atic SCA1 mice and did not cause gross anatomical or
behavioral abnormalities besides the improvement of
motor performance in symptomatic SCA1 mice. Thus,
Ro0711401 might be considered as a prototypical com-
pound for the development of new symptomatic drugs in
the treatment of SCA1 and perhaps other cerebellar
disorders.We were surprised to find that the motor improving
effect of Ro0711401 lasted well beyond the time of drug
clearance from the cerebellar tissue and was still seen
6 days following a single injection. This long-term effect
of Ro0711401 was not associated with an up-regulation
of mGlu1 receptors in Purkinje cells and could not be
ascribed to the disappearance of mGlu5 receptors be-
cause treatment with VU0360172 caused a short-lasting
improvement of motor performance. In addition, pharma-
cological inhibition of mGlu5 receptors has no effect on
motor coordination in EAE mice, in which mGlu5 recep-
tors are also up-regulated [39]. Ro0711401 could facilitate
the induction of cerebellar LTD during the repeated exe-
cution of motor tasks at the rotarod, thereby inducing a
form of procedural memory, which might be formed ini-
tially in the cerebellar cortex and then transferred to
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memory [47]. During LTD induction, the glutamate re-
leased from parallel fibers activates perisynaptic mGlu1
receptors in the distal dendrites of Purkinje cells with
ensuing mobilization of intracellular Ca2+ and activa-
tion of PKC. The conjunctive activation of climbing fi-
bers provides an additional source of intracellular Ca2+
mediated by the opening of voltage-sensitive Ca2+
channels. PKC activation phosphorylates the GluA2
subunit of AMPA receptors leading to AMPA receptor
internalization. The DAG generated by inositol phospholipid
hydrolysis is also a metabolic source for the endocannabi-
noid, 2-arachidonylglycerol, which contributes to depress
synaptic transmission by activating presynaptic CB1 recep-
tors [32,48,49]. Chung et al. [33] have shown for the first
time that phosphorylation of the GluA2 subunit, on Ser
880 within its C-terminal PSD-95/Disc Large/Zona
Occludens-1 (PDZ) ligand, by PKCα is required for the
induction of LTD. This phosphorylation promotes
AMPA receptor endocytosis, a process that is tightly
regulated by a number of GluA2-interacting proteins,
such as protein interacting with C-kinase 1 (PICK1),
N-ethylmaleimmide-sensitive factor (NSF), and glu-
tamate receptor-interacting proteins (GRIP) 1 and 2
[34-36]. We found that Ro0711401 treatment in SCA1
mice enhanced Ser 880 phosphorylation of the GluA2
subunit within the context of increased total GluA2
levels. This suggests that pharmacological enhance-
ment of mGlu1 receptors enriches AMPA receptors of
the Ca2+-impermeable GluA2 subunit, and that phos-
phorylation of GluA2 subunit on Ser 880 commits
AMPA receptors to endocytosis. Another finding that
is suggestive of an LTD-promoting activity of mGlu1
receptor enhancement is the different distribution pro-
file of dendritic spine length in Purkinje cells between
SCA1 mice treated with vehicle and those treated with
Ro0711401. Recent studies suggest that genetic manipu-
lations causing defective LTD of the parallel fiber-Purkinje
cell synapses and impairment of motor learning and
motor coordination lead to an increased number and
length of dendritic spines in Purkinje cells [50,51]. We an-
alyzed a fixed number of dendritic spines per mouse, and,
therefore, we could not determine the real number of
spines in distal dendrites in our groups of mice. However,
we found a higher proportion of long dendritic spines
(0.7-1 μm) in symptomatic SCA1 mice treated with ve-
hicle with respect to wild-type littermates. In contrast,
SCA1 mice treated with Ro0711401 showed a higher pro-
portion of short dendritic spines (0.3-0.5 μm) similarly to
what found in wild-type mice. However, we wish to high-
light that the relationship between the number and shape
of dendritic spines in Purkinje cells and cerebellar LTD is
debated, and two-photon microscopy analysis failed to
detected changes in dendritic spines after synaptic orchemical LTD at the parallel fiber-Purkinje cell synap-
ses, and manipulations that caused persistent retractions
of dendritic spines did not alter parallel fiber-evoked post-
synaptic currents [52].
Conclusions
The prolonged motor improvement induced by Ro0711401
strongly encourages the development of mGlu1 receptor
PAMs for the treatment of SCA1. There is currently no
cure for this disorder and there is no way of slowing its
progression. Some associated symptoms, such as extrapyr-
amidal motor symptom, anxiety and sleep disturbances can
be treated medically, but, to our knowledge, there are no
drugs that specifically target the defect in cerebellar motor
programming underlying ataxia and other cerebellar symp-
toms associated with SCA1. Putative “cerebellomodulatory”
drugs, such as buspirone, zolpidem, riluzole, and amanta-
dine (all of these have indications for other disorders) were
found to have no effect on motor performance in SCA1
mutant mice [53]. Beneficial effects on motor symptoms
and Purkinje cell degeneration were found with the potas-
sium channel blocker, 3,4-diaminopyridine [54]. This drug
is used for the treatment of Lambert-Eaton myasthenic
syndrome with an acceptable profile of safety and tolerabil-
ity, although epileptic seizures and arrhythmias are experi-
enced in response to 3,4-diaminopyridine as a result of the
widespread expression of type-A potassium channel Kv4.3
in excitable cells [55]. Lithium treatment can also improve
motor symptoms in SCA1 mice by apparently targeting
pyramidal neurons in the hippocampus [56]. Lithium
treatment, however, can induce long-lasting neuro-
logical sequelae, the most frequent of which is a per-
manent cerebellar syndrome characterized by Purkinje
cells degeneration [57].
mGlu1 receptor PAMs are excellent candidates as
symptomatic drugs in SCA1 for the following reasons:
(i) expression of mGlu1 receptors is prominent in cere-
bellar Purkinje cells, and these receptors play a key role
in mechanisms of activity-dependent synaptic plasticity
underlying motor learning; (ii) mGlu1 receptors are dir-
ectly linked to the pathophysiology of SCA1 (see Intro-
duction and references therein); (iii) all mGlu receptor
ligands tested in clinical trials have shown, in general, a
good profile of safety and tolerability [5]; (iv) a clear ad-
vantage of a PAM is that this type of drug acts in an
activity-dependent fashion by discriminating receptors
that are recruited into function by the endogenous glu-
tamate with respect to those that are not active (see
above); and (v) as opposed to other receptor subtypes,
mGlu1 receptors have no recognized role in peripheral
organs [58], with the exception of melanoma cells in
which these receptors are ectopically expressed [59,60].
Thus, our findings may lay the groundwork for the de-
sign of cerebellum-specific, effective, and safe symptomatic
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The selective positive allosteric modulator of mGlu1
receptor Ro0711401 [9H-xanthene-9-carboxylic acid
(trifluomethyl-oxazol-2-yl)amide] was kindly provided by




carboxamide hydrochloride) were purchased from Tocris
Cookson (Avonmouth, Bristol, UK). All other chemicals
products were purchased from Sigma-Aldrich (S. Louis,
MO).
Animals
Heterozygous B6.129S-Atxn1tm1Hzo/J mice (stock num-
ber 005601) were obtained from The Jackson Laboratory
(Bar Harbor, ME). Wild-type littermates were generated
from the colony. mGlu1 receptor-deficient crv4 mice and
their wild-type counterparts were provided by A.M.P.
(Gaslini Institute, Genoa, Italy). The crv4 mutation is a
spontaneous recessive mutation consisting of a retrotrans-
poson long terminal repeat fragment insertion that dis-
rupts the splicing of the mGlu1 receptor gene (Grm1) and
causes the absence of the protein [17]. Mice were kept
under environmentally controlled conditions (ambient
temperature, 22°C; humidity, 40%) on a 12 h light/dark
cycle with food and water ad libitum. All experiments
were carried out according to the European (86/609/
EEC) and Italian (D:Lgs. 116/92) guidelines of animal
care. The experimental protocol was approved by the
Italian Ministry of Health (D.M.209/2011-B). All ef-
forts were made to minimize animal suffering and the
number of animals used. SCA1 mice were studied at 4
and 30 week of age and compared with wild-type litter-
mates. Eight week old crv4 mice and their wild-type
counterparts were used as reference mice to exclude
off-target effects of Ro0711401.
Experimental design
Different groups of pre-symptomatic SCA1 mice (4-week
old), symptomatic SCA1 mice (30-week old) and their
wild-type littermates were used for the analysis of mGlu1
and mGlu5 receptor expression in the cerebellum. Add-
itional groups of symptomatic SCA1 mice and wild-type
littermates were treated systemically with one of the
following compounds: the mGlu1 receptor positive allo-
steric modulator (PAM), Ro0711401 (10 mg/kg, s.c.), the
mGlu1 receptor negative allosteric modulator (NAM),
JNJ16259685 (2.5 mg/kg, i.p.), or the mGlu5 receptor
PAM, VU0360172 (10 mg/kg, s.c.). Ro0711401 wasdissolved in peanut oil; JNJ16259685 was dissolved in
saline containing 10% hydroxypropyl-β-cyclodextrin;
VU0360172 was dissolved in 10% Tween 80. Control
mice were treated with the respective vehicles s.c. or
i.p. Some groups of mice (typically 4–6 mice for
groups) received a single injection of each of the
three drugs, and motor performance was assessed at
different post injection times (from 30 min to 6 days).
Independent groups of symptomatic SCA1 mice re-
ceived daily injection of vehicle or Ro0711401, and
motor behavior was assessed 1 hour after a single injec-
tion. The same groups of SCA1 mice and wild-type litter-
mates acutely treated with vehicle or Ro0711401 which
were used for the assessment of motor behavior up to
6 day post-injection were also used for measurement of
mGlu1 and mGlu5 receptors, GluA2 subunit of AMPA re-
ceptor and the length of dendritic spines in Purkinje cells.
One independent group of SCA1 mice was used for mea-
surements of Ro0711401 levels in the cerebellum after a
single drug injection. To test the specificity of mGlu1 re-
ceptor PAM, we examined motor performance 1 hour
after a single injection of Ro0711401 in mice lacking
mGlu1 receptor (crv4) and their wild-type littermates.
Finally, independent groups of wild-type mice were
used to examine the effect of single and repeated injec-
tions of JNJ16259685 on mGlu5 receptor expression in
the cerebellum. In these particular experiments, a first
group of wild-type mice received daily injections of ve-
hicle for 6 days. A second group of mice received daily
injections of vehicle for 5 days followed by a single in-
jection of JNJ16259685. A third group received daily
injections of JNJ16259685 for 5 days.
Real-time RT-PCR
Total RNA from the cerebellum was isolated using the
TRIzol reagent (Life Technologies, Monza, Italy) accord-
ing to the manufacturer’s protocol and retrotranscribed
into cDNA by using SuperScript III Reverse Transcript-
ase (Life Technologies). Real-Time RT-PCR was per-
formed on the Step One Plus Applied Biosystems. PCR
was performed by using Power SYBR Green PCR Master
Mix Kit (Life Technologies) according to the manufac-
turer’s instructions. Real-time PCR was performed by
using the following primers:
mGlu1α/β receptors: forward, 5′-CATACGGAAAGG
GGAAGTGA-3′; reverse, 5′-AAAAGGCGATGGCTAT
GATG-3′. mGlu5 receptors: forward, 5′-ACGAAGAC
CAACCGTATTGC-3′; reverse, 5′-AGACTTCTCGGAT
GCTTGGA-3′. Calbindin: forward, 5′-GGAGCTATCA
CCGGAAATGA-3′; reverse, 5′-AGTTGCTGGCATCG
AAAGAG-3′. GAPDH: forward, 5′-CGTCCCGTAGAC
AAAATGGT-3′; reverse, 5′-TCAATGAAGGGGTCGT
TGAT-3′. mRNA levels were calculated from serially di-
luted standard curves simultaneously amplified with the
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mRNA levels.Western blot analysis
The cerebella were dissected out and homogenized at 4°C
in Tris–HCl buffer containing 1 mM PMSF, pH 7.4, and
an aliquot was used for protein determinations. Equal
amounts of proteins (30 μg) from supernatants were sepa-
rated by 8% SDS polyacrilamide gel for the detection of
mGlu1α receptors, mGlu5 receptors, GluA2 AMPA re-
ceptor subunit, and (Ser880)phosphorylated-GluA2 sub-
unit using a mini-gel apparatus (Bio-Rad Mini Protean II
cell). Proteins were than electroblotted on Immuno PVDF
membranes (Bio-Rad, Milano, Italy) for 1 hour using a
semi-dry electroblotting system (Bio-Rad). Filters were
washed three times and blocked for 1 hour in Tris-Tween
buffered saline (TTBS) containing 5% non-fat dry milk.
The following primary antibodies were used: rabbit
polyclonal anti-mGlu1α antibody (1 μl/ml, Upstate
Biotechnology, Lake Placid, NY); rabbit polyclonal
anti-mGlu5 antibody (1 μl/ml, Upstate Biotechnology);
rabbit polyclonal anti-GluA2 (1 μl/ml, Upstate Biotechnology)
antibody; rabbit polyclonal anti-phospho-GluA2 (Ser880)
(1:500, Upstate Biotechnology) antibody. Filters were
washed three times with TTBS buffer and then incu-
bated for 1 hour with secondary peroxidise-coupled
anti-rabbit antibodies (anti-rabbit 1:7000 Calbiochem,
Milano, Italy). Immunostaining was revealed by enhanced
chemiluminescence luminosity (Amersham Pharmacia
Biotech, Arlington Height, IL). The blots were re-
probed with monoclonal anti β-actin antibody (1:250,
Sigma, St. Louis, MO).Immunohistochemistry
For cerebellum paraffined slices, serial sections were
deparaffinized and soaked in 3% hydrogen peroxide to
block endogenous peroxidase activity, incubated over-
night with anti-mGlu1α or mGlu5 receptor antibodies
(both at 1:100) or with mouse polyclonal anti-calbindin
antibody (1:500; Abcam, Cambridge, UK), and then
incubated for 1 hour with secondary biotinylated anti-
rabbit antibodies (1:200; Vector Laboratories, Burlingame,
CA). Control staining was performed without primary
antibodies. The immunoreaction was carried out with
3,3-diaminobenzidine tetrachloride (ABC Elite kit; Vector
Laboratories).
For frozen serial sections, the cerebellum was re-
moved, post-fixed overnight in 4% PFA, placed in 30%
sucrose/0.1 M phosphate buffer for 24 hours and cryo-
sectioned. Slices were stained with primary anti-mGlu1α
receptor, anti-mGlu5 receptor, anti-calbindin, followed
by the appropriate fluorescent secondary antibodies. All
images were captured using a Zeiss Carl Axiophot2microscopy (Zeiss, Gottingen, Germany) and processed
with NIS-elements F3.0.
Confocal microscopy
Mice were perfused with ice-cold 4% paraformaldehyde,
and equilibrate with 30% sucrose overnight. Cerebellum
was sectioned using a Leica cryostat (CM3050). For im-
munofluorescence analysis, serial sections were incu-
bated with blocking solution (5% normal serum in 0.30%
Triton X-100 in PBS) and then with the following anti-
bodies overnight at 4°C: anti-calbindin (1:500, Abcam),
anti-vGluT2 (1:250, Millipore, Temecula, CA), anti-
mGlu5 receptor (1:200, Abcam). After washing, sections
were incubated with secondary antibodies conjugated
with Alexa Fluor 488 (1:200, Invitrogen) and Cy3
(1:200, Jackson immunoResearch, Suffolk, UK) for 2 hours
at room temperature and rinsed in PBS. Finally sections
were mounted with anti-fading agent (Vector) and exam-
ined with Olympus FV1000 spectral confocal laser scan-
ning microscope.
Golgi staining
Five mice per group were deeply anesthetized with
320 mg/kg of chloral hydrate and perfused with 0.9% sa-
line. Brains were removed and placed in 20 ml Golgi-
Cox solution [61]. The brains were stored in the dark
for 3 weeks and refreshing solutions every 2–3 days,
after which the Golgi-Cox solution was replaced with
30% sucrose. The brains were allowed to sit in the dark
for 2–5 days before sectioning at vibratome and process-
ing for the staining in according with Gibb and Kolb
[62]. Distal, third or fourth order dendrites, were used
for the evaluation of spine length, defining a spine as a
protrusion clearly originating from the shaft of a den-
drite and not intersecting any other dendritic segment;
moreover, we did not measure any spine that appears to
contain more than one head [50]. Spines were identified
and measured using a EC-Plan Neofluar 100×, 1,3 NA
oil immersion objective (Zeiss). Measurement was per-
formed using Image Pro Plus Software (Media Cybernet-
ics, Rockville, MD). We captured images of ten cells for
animal, and for each cell, we measured the length in
twenty spines, for a total of two-hundred spines mea-
sured for animal. The corresponding values from ten
cells per animal were averaged, and the average of the
five animal per group was used for statistical analysis.
Statistical analysis were performed using Two-Way
ANOVA analysis of variance, followed by Bonferroni’s
post tests.
Measurement of spine density
Dendritic protrusions were quantified in terms of den-
dritic spines density. These were counted in 50 μm from
3 to 4 dendritic branchlets of cerebellar Purkinje cells.
Table 2 Monitored ion transitions and their parameter
settings of mass spectrometer for the detection and
measurements of Ro0711401
Precursor ion Fragment DP EP CE CXP
(m/z, amu) (m/z, amu) (V) (V) (V) (V)
RO (361.0) 181.1 47.0 5.8 25.0 2.9
153.0 47.0 5.8 19.1 2.8
IS (351.2) 234.0 42.0 7.0 23.7 3.2
170.0 42.0 7.0 26 2.6
DP – Declustering Potential; EP – Entrance Potential; CE – Collision Energy;
CXP – Collision Cell Exit Potential.
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50 μm in length, more than one segment per cell were
selected until reaching the measure established of
50 μm. These segments were selected randomly. Counting
was performed by direct observation in ten cells per ani-
mal. Statistical analysis were performed using One-Way




The cerebellum was homogenated with 1 ml of 0.1%
aqueous formic acid. For each sample, weight was re-
corded. Thirty μl of tissue homogenates were added to
150 μl of internal standard working solution (1 mM dan-
silnorvaline in 100% acetonitrile). After extensive vortex
(60 sec), samples were centrifuged at 14,000 revolutions
per minute (rpm) for 5 min. Forty μl of supernatant
were mixed with 160 μl of 0.1% aqueous formic acid and
transferred to an autosampler vial for injection into the
chromatographic system.
Chromatographic conditions
The HPLC analysis was performed using an Agilent Liquid
Chromatography System series 1100 (Agilent Technologies,
Santa Clara, CA), with a binary pump, an autosampler, a
solvent degasser and a column oven. The chromatographic
separation was performed using a 50 × 2.0 mm, Luna C18,
5 μm, 100 Å pore size column (Phenomenex, Torrance,
CA), equipped with Security guard precolumn (Phenom-
enex), containing the same packing material. The column
was maintained at room temperature. The mobile phase
was a solution of 0.1% aqueous formic acid (eluent A) and
100% acetonitrile (eluent B). Injection volume consisted of
20 μl; elution was performed at flow rate of 300 μl/min,
using 10% solvent B for 1 min, linear gradient to 90% solv-
ent B for 3 min, 90% solvent B for 2 min and after-
wards re-equilibrating with 90% solvent A for 4 min.
The total analysis run time was 10 min.
Mass spectrometry conditions
The mass spectrometry was performed on a 3200 triple
quadrupole system (Applied Biosystems, Foster City,
CA), equipped with a Turbo Ion Spray source. Data were
acquired and processed with Analyst 1.4.2 software. The
detector was set in the positive ion mode. The ion spray
voltage was set at 5000 V and the source temperature
was 300°C. The collision activation dissociation (CAD)
gas was set at medium value and nitrogen was used as
collision gas. The Q1 and Q3 quadrupoles were tuned
for the unit mass resolution. The transitions of the pre-
cursor ions to the product ions were monitored with a
dwell time of 100 ms for each analyte. The instrument
was set in the multiple reaction monitoring (MRM)mode. Mass spectrometer parameters were optimized to
maximize sensitivity for all transitions (Table 2).
A calibration curve was established using known con-
centration (0, 6.25, 12.5, 25, 50, 100, 250, 500, 1000 ng/ml)
of Ro0711401 dissolved in 0,1% aqueous formic acid and
processed in the same way of tissue samples. The equation
of linear regression obtained for this value range was
y = 0.000204× + 0.0033 (r = 0.9982).Assessment of motor coordination in SCA1 mice
Rotarod test
Motor ability was assessed using an accelerating Rotarod
apparatus, as described [63]. Mice were forced to man-
age an accelerating rotarod to monitor motor perform-
ance. The rotarod apparatus consisted of a rotating
horizontal cylinder (30 mm) and a motor driver control
unit (Ugo Basile, Varese, Italy). The cylinder was divided
into 5 separate rotating compartments, fully enclosed to
ensure that the mice did not jump out of their area. The
mice were placed on the rod which was rotating at ac-
celerating speed from 5 to 15 rpm. Automatic timers re-
corded the duration of time the mice remained on the
rod, and two infrared beams at the base of each com-
partment determined when the mice had fallen off the
rod. Mice were tested using four trials per day (10 min
rests between trials) on 4 consecutive days. During a
trial, the rod accelerated from 4 to 40 rpm over 5 min.
Each trial lasted until the mouse fell from the rod or for
a maximum of 5 min.Paw printing test
Paw prints were made with ink and water color paper.
Ink was applied to the hind paws of individual mice
which were then induced to walk forward, leaving a rec-
ord on the paper [15]. The test was carried out twice
soon after the Rotarod test. Data were quantified by cal-
culating the coefficient of variation (the ratio between
standard deviation and the mean value) of five consecu-
tive strides with the left paw.
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Statistical analysis were carried out by using the Stu-
dent’s t test (Figures 1, 2, 8); paired t-test (Figure 3);
One-Way ANOVA (Figures 3, 6) or Two-Way ANOVA
for repeated measures followed by Fisher’s LSD (Figures 3,
4, 5) or followed Bonferroni’s t-test (Figure 8); p values <
0.05 were considered significant.
Abbreviation
mGlu: Metabotropic glutamate; SCA1: Spinocerebellar ataxia type-1;
PAM: Positive allosteric modulator; NAM: Negative allosteric modulator;
ATXN1: Ataxin-1; InsP3: Inositol-1,4,5-trisphosphate; DAG: Diacylglicerol;
PKC: Protein kinase C; AMPA: 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)
propanoic acid; LTD: Long term depression.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SN, CZ and FF designed and performed in vivo experiments and analyzed
data. MC and PS performed real-time PCR experiments. FB, DB and FW performed
immunohistochemical analysis. GM and MS performed confocal microscopy
analysis.LL and MS analyzed sample by HPLC. RG and GB contributed to
experiment design and supervised research. FN designed experiments, supervised
research and wrote the manuscript. All authors read and approved the final
manuscript.
Acknowledgments
We are grateful to Hoffmann La Roche Ltd, Pharmaceutical Division, Basel
Switzerland, for kindly providing Ro0711401. We would also like to thank M.
Ulivieri for technical support.
Author details
1I.R.C.C.S. Neuromed, Pozzilli, Italy. 2Department of Physiology and
Pharmacology, University “Sapienza”, Piazzale Aldo Moro, 5, 00185 Rome,
Italy. 3Department of Neuroscience, Mental Health and Sensory Organs,
Advanced Molecular Diagnostics, Azienda Ospedale S. Andrea, Rome, Italy.
4Department of Experimental Medicine, University “Sapienza”, Rome, Italy.
5Department of Hematology, Oncology and Molecular Medicine, Istituto
Superiore di Sanità, Rome, Italy. 6Molecular Genetics and Cytogenetics Unit,
Gaslini Institute, Genoa, Italy.
Received: 9 August 2013 Accepted: 28 October 2013
Published: 19 November 2013
References
1. Orr HT, Chung MY, Banfi S, Kwiatkowski TJ Jr, Servadio A, Beaudet AL,
McCall AE, Duvick LA, Ranum LP, Zoghbi HY: Expansion of an unstable
trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 1993,
4:221–226.
2. Koeppen AH: The pathogenesis of spinocerebellar ataxia. Cerebellum 2005,
4:62–73.
3. Watase K, Weeber EJ, Xu B, Antalffy B, Yuva-Paylor L, Hashimoto K, Kano M,
Atkinson R, Sun Y, Armstrong DL, Sweatt JD, Orr HT, Paylor R, Zoghbi HY: A
long CAG repeat in the mouse Sca1 locus replicates SCA1 features and
reveals the impact of protein solubility on selective neurodegeneration.
Neuron 2002, 34:905–919.
4. Nelson DL, Orr HT, Warren ST: The unstable repeats–three evolving faces
of neurological disease. Neuron 2013, 77:825–843.
5. Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD,
Wroblewski JT, Pin JP: Metabotropic glutamate receptors: from the
workbench to the bedside. Neuropharmacology 2011, 60:1017–1041.
6. Nakanishi S, Nakajima Y, Masu M, Ueda Y, Nakahara K, Watanabe D,
Yamaguchi S, Kawabata S, Okada M: Glutamate receptors: brain function
and signal transduction. Brain Res Rev 1998, 26:230–235.
7. Baude A, Nusser Z, Roberts JD, Mulvihill E, McIlhinney RA, Somogyi P: The
metabotropic glutamate receptor (mGluR1 alpha) is concentrated at
perisynaptic membrane of neuronal subpopulations as detected by
immunogold reaction. Neuron 1993, 11:771–787.8. Ferraguti F, Crepaldi L, Nicoletti F: Metabotropic glutamate 1
receptor: current concepts and perspectives. Pharmacol Rev 2008,
60:536–581.
9. Casabona G, Knöpfel T, Kuhn R, Gasparini F, Baumann P, Sortino MA, Copani
A, Nicoletti F: Expression and coupling to polyphosphoinositide
hydrolysis of group I metabotropic glutamate receptors in early
postnatal and adult rat brain. Eur J Neurosci 1997, 9:12–17.
10. Karachot L, Shirai Y, Vigot R, Yamamori T, Ito M: Induction of long-term
depression in cerebellar Purkinje cells requires a rapidly turned over
protein. J Neurophysiol 2001, 86:280–289.
11. Ichise T, Kano M, Hashimoto K, Yanagihara D, Nakao K, Shigemoto R, Katsuki
M, Aiba A: mGluR1 in cerebellar Purkinje cells essential for long-term
depression, synapse elimination, and motor coordination. Science
2000, 288:1832–1835.
12. Hansel C, Linden DJ: Long-term depression of the cerebellar climbing
fiber-Purkinje neuron synapse. Neuron 2000, 26:473–482.
13. Linden DJ, Connor JA: Participation of postsynaptic PKC in cerebellar
long-term depression in culture. Science 1991, 254:1656–1659.
14. Nakanishi S: Synaptic mechanisms of the cerebellar cortical network.
Trends Neurosci 2005, 28:93–100.
15. Aiba A, Kano M, Chen C, Stanton ME, Fox GD, Herrup K, Zwingman TA,
Tonegawa S: Deficient cerebellar long-term depression and impaired
motor learning in mGluR1 mutant mice. Cell 1994, 79:377–388.
16. Conquet F, Bashir ZI, Davies HC, Daniel H, Ferraguti F, Bordi F, Franz-Bacon
K, Reggiani A, Matarese V, Condé F, Collingridge GL, Crépe LF: Motor deficit
and impairment of synaptic plasticity in mice lacking mGluR1. Nature
1994, 372:237–243.
17. Conti V, Aghaie A, Cilli M, Martin N, Caridi G, Musante L, Candiano G,
Castagna M, Fairen A, Ravazzolo R, Guenet JL, Puliti A: Crv4, a mouse
model for human ataxia associated with kyphoscoliosis caused by an
mRNA splicing mutation of the metabotropic glutamate receptor 1
(Grm1). Int J Mol Med 2006, 18:593–600.
18. Kishimoto Y, Fujimichi R, Araishi K, Kawahara S, Kano M, Aiba A, Kirino Y:
mGluR1 in cerebellar Purkinje cells is required for normal association of
temporally contiguous stimuli in classical conditioning. Eur J Neurosci
2002, 16:2416–2424.
19. Sachs AJ, Schwendinger JK, Yang AW, Haider NB, Nystuen AM: The mouse
mutants recoil wobbler and nmf373 represent a series of Grm1
mutations. Mamm Genome 2007, 18:749–756.
20. Kurnellas MP, Lee AK, Li H, Deng L, Ehrlich DJ, Elkabes S: Molecular
alterations in the cerebellum of the plasma membrane calcium ATPase 2
(PMCA2)-null mouse indicate abnormalities in Purkinje neurons. Mol Cell
Neurosci 2007, 34:178–188.
21. Mitsumura K, Hosoi N, Furuya N, Hirai H: Disruption of metabotropic
glutamate receptor signalling is a major defect at cerebellar parallel
fibre-Purkinje cell synapses in staggerer mutant mice. J Physiol 2011,
589:3191–3209.
22. Sillevis Smitt P, Kinoshita A, De Leeuw B, Moll W, Coesmans M, Jaarsma D,
Henzen-Logmans S, Vecht C, De Zeeuw C, Sekiyama N, Nakanishi S,
Shigemoto R: Paraneoplastic cerebellar ataxia due to autoantibodies against
a glutamate receptor. N Engl J Med 2000, 342:21–27.
23. Skinner PJ, Vierra-Green CA, Clark HB, Zoghbi HY, Orr HT: Altered trafficking
of membrane proteins in purkinje cells of SCA1 transgenic mice. Am J
Pathol 2001, 159:905–913.
24. Zu T, Duvick LA, Kaytor MD, Berlinger MS, Zoghbi HY, Clark HB, Orr HT:
Recovery from polyglutamine-induced neurodegeneration in conditional
SCA1 transgenic mice. J Neurosci 2004, 24:8853–8861.
25. Lin X, Antalffy B, Kang D, Orr HT, Zoghbi HY: Polyglutamine expansion
down-regulates specific neuronal genes before pathologic changes in
SCA1. Nat Neurosci 2000, 3:157–163.
26. Serra HG, Byam CE, Lande JD, Tousey SK, Zoghbi HY, Orr HT: Gene profiling
links SCA1 pathophysiology to glutamate signaling in Purkinje cells of
transgenic mice. Hum Mol Genet 2004, 13:2535–2543.
27. Sheffler DJ, Gregory KJ, Rook JM, Conn PJ: Allosteric modulation of
metabotropic glutamate receptors. Adv Pharmacol 2011, 62:37–77.
28. Wood MR, Hopkins CR, Brogan JT, Conn PJ, Lindsley CW: “Molecular
switches” on mGluR allosteric ligands that modulate modes of
pharmacology. Biochemistry 2011, 50:2403–2410.
29. Gregory KJ, Dong EN, Meiler J, Conn PJ: Allosteric modulation of
metabotropic glutamate receptors: structural insights and therapeutic
potential. Neuropharmacology 2011, 60:66–81.
Notartomaso et al. Molecular Brain 2013, 6:48 Page 17 of 17
http://www.molecularbrain.com/content/6/1/4830. Kano M, Hashimoto K, Kurihara H, Watanabe M, Inoue Y, Aiba A, Tonegawa
S: Persistent multiple climbing fiber innervation of cerebellar Purkinje
cells in mice lacking mGluR1. Neuron 1997, 18(1):71–79.
31. Ebner BA, Ingram MA, Barnes JA, Duvick LA, Frisch JL, Clark HB, Zoghbi HY,
Ebner TJ, Orr HT: Purkinje cell ataxin-1 modulates climbing fiber synaptic
input in developing and adult mouse cerebellum. J Neurosci 2013,
33(13):5806–5820. 27.
32. Matsuda S, Launey T, Mikawa S, Hirai H: Disruption of AMPA receptor
GluR2 clusters following long-term depression induction in cerebellar
Purkinje neurons. EMBO J 2000, 19:2765–2774.
33. Chung HJ, Steinberg JP, Huganir RL, Linden DJ: Requirement of AMPA
receptor GluR2 phosphorylation for cerebellar long-term depression.
Science 2003, 300:1751–1755.
34. Steinberg JP, Huganir RL, Linden DJ: N-ethylmaleimide-sensitive factor is
required for the synaptic incorporation and removal of AMPA receptors
during cerebellar long-term depression. Proc Natl Acad Sci USA 2004,
101:18212–18216.
35. Steinberg JP, Takamiya K, Shen Y, Xia J, Rubio ME, Yu S, Jin W, Thomas GM,
Linden DJ, Huganir RL: Targeted in vivo mutations of the AMPA receptor
subunit GluR2 and its interacting protein PICK1 eliminate cerebellar
long-term depression. Neuron 2006, 49:845–860.
36. Tatsukawa T, Chimura T, Miyakawa H, Yamaguchi K: Involvement of basal
protein kinase C and extracellular signal-regulated kinase 1/2 activities
in constitutive internalization of AMPA receptors in cerebellar Purkinje
cells. J Neurosci 2006, 26:4820–4825.
37. Takamiya K, Mao L, Huganir RL, Linden DJ: The glutamate receptor-
interacting protein family of GluR2-binding proteins is required for
long-term synaptic depression expression in cerebellar Purkinje cells.
J Neurosci 2008, 28:5752–5755.
38. Catania MV, Landwehrmeyer GB, Testa CM, Standaert DG, Penney JB Jr,
Young AB: Metabotropic glutamate receptors are differentially regulated
during development. Neuroscience 1994, 61:481–495.
39. Fazio F, Notartomaso S, Aronica E, Storto M, Battaglia G, Vieira E, Gatti S,
Bruno V, Biagioni F, Gradini R, Nicoletti F, Di Marco R: Switch in the
expression of mGlu1 and mGlu5 metabotropic glutamate receptors in
the cerebellum of mice developing experimental autoimmune
encephalomyelitis and in autoptic cerebellar samples from patients with
multiple sclerosis. Neuropharmacology 2008, 55:491–499.
40. Kawabata S, Tsutsumi R, Kohara A, Yamaguchi T, Nakanishi S, Okada M:
Control of calcium oscillations by phosphorylation of metabotropic
glutamate receptors. Nature 1996, 383:89–92.
41. Berridge MJ, Galione A: Cytosolic calcium oscillators. FASEB J 1988, 2:3074–3082.
42. Berridge MJ, Bootman MD, Roderick HL: Calcium signalling: dynamics,
homeostasis and remodelling. Nat Rev Mol Cell Biol 2003, 4:517–529.
43. Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R,
Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook
JM, Stauffer SR, Niswender CM, Lindsley CW, Weaver CD, Conn PJ:
Discovery of novel allosteric modulators of metabotropic glutamate
receptor subtype 5 reveals chemical and functional diversity and in vivo
activity in rat behavioral models of anxiolytic and antipsychotic activity.
Mol Pharmacol 2010, 78:1105–1123.
44. D’Amore V, Santolini I, van Rijn CM, Biagioni F, Molinaro G, Prete A, Conn PJ,
Lindsley CW, Zhou Y, Vinson PN, Rodriguez AL, Jones CK, Stauffer SR,
Nicoletti F, van Luijtelaar G, Ngomba RT: Potentiation of mGlu5 receptors
with the novel enhancer, VU0360172, reduces spontaneous absence
seizures in WAG/Rij rats. Neuropharmacology 2013, 66:330–338.
45. Vieira E, Huwyler J, Jolidon S, Knoflach F, Mutel V, Wichmann J: Fluorinated:
9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available
mGlu1 receptor enhancers. Bioorg Med Chem Lett 2009, 19:1666–1669.
46. Ngomba RT, Santolini I, Biagioni F, Molinaro G, Simonyi A, van Rijn CM,
D’Amore V, Mastroiacovo F, Olivieri G, Gradini R, Ferraguti F, Battaglia G,
Bruno V, Puliti A, van Luijtelaar G, Nicoletti F: Protective role for type-1
metabotropic glutamate receptors against spike and wave discharges
in the WAG/Rij rat model of absence epilepsy. Neuropharmacology
2011, 60:1281–1291.
47. Shutoh F, Ohki M, Kitazawa H, Itohara S, Nagao S: Memory trace of motor
learning shifts transsynaptically from cerebellar cortex to nuclei for
consolidation. Neuroscience 2006, 139(2):767–777.
48. Wang YT, Linden DJ: Expression of cerebellar long-term depression requires
postsynaptic clathrin-mediated endocytosis. Neuron 2000, 25:635–647.49. Kano M, Hashimoto K, Tabata T: Type-1 metabotropic glutamate receptor
in cerebellar Purkinje cells: a key molecule responsible for long-term
depression, endocannabinoid signalling and synapse elimination.
Philos Trans R Soc Lond B Biol Sci 2008, 363:2173–2186.
50. McEvoy M, Cao G, Montero Llopis P, Kundel M, Jones K, Hofler C, Shin C,
Wells DG: Cytoplasmic polyadenylation element binding protein
1-mediated mRNA translation in Purkinje neurons is required for
cerebellar long-term depression and motor coordination. J Neurosci
2007, 27:6400–6411.
51. Sugawara T, Hisatsune C, Le TD, Hashikawa T, Hirono M, Hattori M, Nagao S,
Mikoshiba K: Type 1 inositol trisphosphate receptor regulates cerebellar
circuits by maintaining the spine morphology of purkinje cells in adult
mice. J Neurosci 2013, 33:12186–12196.
52. Sdrulla AD, Linden DJ: Double dissociation between long-term depression
and dendritic spine morphology in cerebellar Purkinje cells. Nat Neurosci
2007, 10:546–548.
53. Nag N, Tarlac V, Storey E: Assessing the efficacy of specific
cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia
type 1. Cerebellum 2013, 12:74–82.
54. Hourez R, Servais L, Orduz D, Gall D, Millard I, de Kerchove d’Exaerde A,
Cheron G, Orr HT, Pandolfo M, Schiffmann SN: Aminopyridines correct
early dysfunction and delay neurodegeneration in a mouse model of
spinocerebellar ataxia type 1. J Neurosci 2011, 31:11795–11807.
55. Wirtz PW, Titulaer MJ, Gerven JM, Verschuuren JJ: 3,4-diaminopyridine for
the treatment of Lambert-Eaton myasthenic syndrome. Expert Rev Clin
Immunol 2010, 6:867–874.
56. Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, Mizusawa
H, Orr HT, Shaw C, Zoghbi HY: Lithium therapy improves neurological
function and hippocampal dendritic arborization in a spinocerebellar
ataxia type 1 mouse model. PLoS Med 2007, 4:e182.
57. Grignon S, Bruguerolle B: Cerebellar lithium toxicity: a review of recent
literature and tentative pathophysiology. Therapie 1996, 51:101–106.
58. Julio-Pieper M, Flor PJ, Dinan TG, Cryan JF: Exciting times beyond the
brain: metabotropic glutamate receptors in peripheral and non-neural
tissues. Pharmacol Rev 2011, 63:35–58.
59. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, Zhu
H, Robbins C, Makalowska I, Shin SS, Marin Y, Roberts KG, Yudt LM, Chen A,
Cheng J, Incao A, Pinkett HW, Graham CL, Dunn K, Crespo-Carbone SM,
Mackason KR, Ryan KB, Sinsimer D, Goydos J, Reuhl KR, Eckhaus M, Meltzer
PS, Pavan WJ, Trent JM, Chen S: Melanoma mouse model implicates me-
tabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003,
34:108–112.
60. Wangari-Talbot J, Wall BA, Goydos JS, Chen S: Functional effects of GRM1
suppression in human melanoma cells. Mol Cancer Res 2012, 10:1440–1450.
61. Glaser EM, Van der Loos H: Analysis of thick brain sections by
obverse–reverse computer microscopy: application of a new, high
clarity Golgi–Nissl stain. J Neurosci Methods 1981, 4:117–125.
62. Gibb R, Kolb B: A method for vibratome sectioning of Golgi–Cox stained
whole rat brain. J Neurosci Methods 1998, 79:1–4.
63. Jones BJ, Roberts DJ: The quantiative measurement of motor inco-ordination
in naive mice using an acelerating rotarod. J Pharm Pharmacol 1968,
20:302–304.
doi:10.1186/1756-6606-6-48
Cite this article as: Notartomaso et al.: Pharmacological enhancement of
mGlu1 metabotropic glutamate receptors causes a prolonged
symptomatic benefit in a mouse model of spinocerebellar ataxia type 1.
Molecular Brain 2013 6:48.
